Top

Cardiovascular Diabetology

Published in:

Open Access 01-12-2020 | Intravascular Ultrasound | Original investigation

Effect of 1,5-anhydroglucitol levels on culprit plaque rupture in diabetic patients with acute coronary syndrome

Authors: Gong Su, Ming-Xi Gao, Gen-Ling Shi, Xi-Xi Dai, Wei-Feng Yao, Tao Zhang, Shao-Wei Zhuang

Published in: Cardiovascular Diabetology | Issue 1/2020

Abstract

Background

Postprandial hyperglycemia was reported to play a key role in established risk factors of coronary artery diseases (CAD) and cardiovascular events. Serum 1,5-anhydroglucitol (1,5-AG) levels are known to be a clinical marker of short-term postprandial glucose (PPG) excursions. Low serum 1,5-AG levels have been associated with occurrence of CAD. However, the relationship between 1,5-AG levels and coronary plaque rupture has not been fully elucidated. The aim of this study was to evaluate 1,5-AG as a predictor of coronary plaque rupture in diabetic patients with acute coronary syndrome (ACS).

Methods

A total of 144 diabetic patients with ACS were included in this study. All patients underwent intravascular ultrasound examination, which revealed 49 patients with plaque rupture and 95 patients without plaque rupture in the culprit lesion. Fasting blood glucose (FBG), hemoglobin A_1c (HbA_1c) and 1,5-AG levels were measured before coronary angiography. Fasting urinary 8-iso-prostaglandin F_2α (8-iso-PGF_2α) level was measured and corrected by creatinine clearance.

Results

Patients with ruptured plaque had significantly lower serum 1,5-AG levels, longer duration of diabetes, higher HbA_1c and FBG levels than patients without ruptured plaque in our study population. In multivariate analysis, low 1,5-AG levels were an independent predictor of plaque rupture (odds ratio 3.421; P = 0.005) in diabetic patients with ACS. The area under the receiver-operating characteristic curve for 1,5-AG (0.658, P = 0.002) to predict plaque rupture was superior to that for HbA_1c (0.587, P = 0.087). Levels of 1,5-AG were significantly correlated with urinary 8-iso-prostaglandin F_2α levels (r = − 0.234, P = 0.005).

Conclusions

Serum 1,5-AG may identify high risk for coronary plaque rupture in diabetic patients with ACS, which suggests PPG excursions are related to the pathogenesis of plaque rupture in diabetes.

Stefanadis C, Antoniou CK, Tsiachris D, Pietri P. Coronary atherosclerotic vulnerable plaque: current perspectives. J Am Heart Assoc. 2017;6(3):e005543.PubMedPubMedCentralCrossRef

Saia F, Komukai K, Capodanno D, Sirbu V, Musumeci G, Boccuzzi G, et al. Eroded versus ruptured plaques at the culprit site of stemi: in vivo pathophysiological features and response to primary PCI. JACC Cardiovasc Imaging. 2015;8(5):566–75.PubMedCrossRef

Higuma T, Soeda T, Abe N, Yamada M, Yokoyama H, Shibutani S, et al. A combined optical coherence tomography and intravascular ultrasound study on plaque rupture, plaque erosion, and calcified nodule in patients with st-segment elevation myocardial infarction: incidence, morphologic characteristics, and outcomes after percutaneous coronary intervention. JACC Cardiovasc Interv. 2015;8(9):1166–76.PubMedCrossRef

Iannaccone M, Quadri G, Taha S, D’Ascenzo F, Montefusco A, Omede’ P, et al. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. Eur Heart J Cardiovasc Imaging. 2016;17(10):1128–37.PubMedCrossRef

Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20(5):1262–75.PubMedCrossRef

Sugiyama T, Yamamoto E, Bryniarski K, Xing L, Fracassi F, Lee H, et al. Coronary plaque characteristics in patients with diabetes mellitus who presented with acute coronary syndromes. J Am Heart Assoc. 2018;7(14):e009245.PubMedPubMedCentralCrossRef

Kim WJ, Park CY. 1,5-Anhydroglucitol in diabetes mellitus. Endocrine. 2013;43(1):33–40.PubMedCrossRef

Fujiwara T, Yoshida M, Yamada H, Tsukui T, Nakamura T, Sakakura K, et al. Lower 1,5-anhydroglucitol is associated with de novo coronary artery disease in patients at high cardiovascular risk. Heart Vessels. 2015;30(4):469–76.PubMedCrossRef

Ikeda N, Hara H, Hiroi Y. 1,5-Anhydro-d-glucitol predicts coronary artery disease prevalence and complexity. J Cardiol. 2014;64(4):297–301.PubMedCrossRef

10.

Selvin E, Rawlings A, Lutsey P, Maruthur N, Pankow JS, Steffes M, et al. Association of 1,5-anhydroglucitol with cardiovascular disease and mortality. Diabetes. 2016;65(1):201–8.PubMedCrossRef

11.

Takahashi S, Shimada K, Miyauchi K, Miyazaki T, Sai E, Ogita M, et al. Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention. Cardiovasc Diabetol. 2016;15(1):145.PubMedPubMedCentralCrossRef

12.

Ouchi S, Shimada K, Miyazaki T, Takahashi S, Sugita Y, Shimizu M, et al. Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0. Cardiovasc Diabetol. 2017;16(1):151.PubMedPubMedCentralCrossRef

13.

Ma T, Zhou B, Hsiai TK, Shung KK. A review of intravascular ultrasound-based multimodal intravascular imaging: the synergistic approach to characterizing vulnerable plaques. Ultrason Imaging. 2016;38(5):314–31.PubMedCrossRef

14.

Tian J, Ren X, Vergallo R, Xing L, Yu H, Jia H, et al. Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study. J Am Coll Cardiol. 2014;63(21):2209–16.PubMedCrossRef

15.

Hong YJ, Jeong MH, Choi YH, Ko JS, Lee MG, Kang WY, et al. Plaque characteristics in culprit lesions and inflammatory status in diabetic acute coronary syndrome patients. JACC Cardiovasc Imaging. 2009;2(3):339–49.PubMedCrossRef

16.

Akanuma Y, Morita M, Fukuzawa N, Yamanouchi T, Akanuma H. Urinary excretion of 1,5-anhydro-d-glucitol accompanying glucose excretion in diabetic patients. Diabetologia. 1988;31(11):831–5.PubMedCrossRef

17.

Kiniwa N, Okumiya T, Tokuhiro S, Matsumura Y, Matsui H, Koga M. Hemolysis causes a decrease in HbA1c level but not in glycated albumin or 1,5-anhydroglucitol level. Scand J Clin Lab Investig. 2019;79(6):377–80.CrossRef

18.

Lorenzo-Almorós A, Hang T, Peiró C, Soriano-Guillén L, Egido J, Tuñón J, et al. Predictive and diagnostic biomarkers for gestational diabetes and its associated metabolic and cardiovascular diseases. Cardiovasc Diabetol. 2019;18(1):140.PubMedPubMedCentralCrossRef

19.

Kim HO, Kim CJ, Kim W, Cho JM, Soeda T, Takano M, et al. Relative risk of plaque erosion among different age and sex groups in patients with acute coronary syndrome. J Thromb Thrombolysis. 2020;49(3):352–9.PubMedCrossRef

20.

Niccoli G, Montone RA, Di Vito L, Gramegna M, Refaat H, Scalone G, et al. Plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome. Eur Heart J. 2015;36(22):1377–84.PubMedCrossRef

21.

Sheng Z, Zhou P, Liu C, Li J, Chen R, Zhou J, et al. Relationships of coronary culprit-plaque characteristics with duration of diabetes mellitus in acute myocardial infarction: an intravascular optical coherence tomography study. Cardiovasc Diabetol. 2019;18(1):136.PubMedPubMedCentralCrossRef

22.

Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006;29(6):1214–9.PubMedCrossRef

23.

Wang Y, Zhang YL, Wang YP, Lei CH, Sun ZL. A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycaemic excursions as measured by continuous glucose monitoring system among people with type 2 diabetes in China. Diabetes Metab Res Rev. 2012;28(4):357–62.PubMedPubMedCentralCrossRef

24.

Wada H, Dohi T, Miyauchi K, Takahashi N, Endo H, Kato Y, et al. Impact of serum 1,5-anhydro-d-glucitol level on the prediction of severe coronary artery calcification: an intravascular ultrasound study. Cardiovasc Diabetol. 2019;18(1):69.PubMedPubMedCentralCrossRef

25.

Reith S, Milzi A, Lemma ED, Dettori R, Burgmaier K, Marx N, et al. Intrinsic calcification angle: a novel feature of the vulnerable coronary plaque in patients with type 2 diabetes: an optical coherence tomography study. Cardiovasc Diabetol. 2019;18(1):122.PubMedPubMedCentralCrossRef

26.

Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2019;7(3):221–30.PubMedCrossRef

27.

Zhang T, Su G, Mi SH, Yang HX, Xin W, Dai WL, et al. Association between blood glucose variability and the characteristics of vulnerable plaque in elderly non-st segment elevation acute coronary syndrome patients. Int Heart J. 2019;60(3):569–76.PubMedCrossRef

28.

Kohata Y, Ohara M, Nagaike H, Fujikawa T, Osaka N, Goto S, et al. Association of hemoglobin A_1c, 1,5-anhydro-d-glucitol and glycated albumin with oxidative stress in type 2 diabetes mellitus patients: a cross-sectional study. Diabetes Ther. 2020;11(3):655–65.PubMedPubMedCentralCrossRef

29.

Pignatelli P, Menichelli D, Pastori D, Violi F. Oxidative stress and cardiovascular disease: new insights. Kardiol Pol. 2018;76(4):713–22.PubMedCrossRef

30.

Su G, Wang T, Zhang T, Yang HX, Yu SS, Dai WL, et al. Urinary 8-iso-prostaglandin F_2α as a risk marker for the vulnerability of culprit plaque in diabetic patients with stable coronary artery disease. Prostaglandins Leukot Essent Fatty Acids. 2019;140(1):11–7.PubMedCrossRef

31.

Nishibe A, Kijima Y, Fukunaga M, Nishiwaki N, Sakai T, Nakagawa Y, et al. Increased isoprostane content in coronary plaques obtained from vulnerable patients. Prostaglandins Leukot Essent Fatty Acids. 2008;78(4–5):257–63.PubMedCrossRef

32.

Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A. Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int. 1999;56(2):471–8.PubMedCrossRef

33.

Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106(16):2067–72.PubMedCrossRef

34.

Teraguchi I, Imanishi T, Ozaki Y, Tanimoto T, Orii M, Shiono Y, et al. Impact of glucose fluctuation and monocyte subsets on coronary plaque rupture. Nutr Metab Cardiovasc Dis. 2014;24(3):309–14.PubMedCrossRef

Title: Effect of 1,5-anhydroglucitol levels on culprit plaque rupture in diabetic patients with acute coronary syndrome
Authors: Gong Su
Ming-Xi Gao
Gen-Ling Shi
Xi-Xi Dai
Wei-Feng Yao
Tao Zhang
Shao-Wei Zhuang
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Intravascular Ultrasound
Acute Coronary Syndrome
Published in: Cardiovascular Diabetology / Issue 1/2020
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-020-01045-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study

The sweet spot: fasting glucose, cardiovascular disease, and mortality in older adults with diabetes: a nationwide population-based study

Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet

Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status: a nationwide population-based study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials